6533b82bfe1ef96bd128e297
RESEARCH PRODUCT
Early and personalized ambulatory follow-up to tailor furosemide and fluid intake according to congestion in post-discharge heart failure
Salvatore PaternaDaniele TorresMauro CardilloGaspare ParrinelloGiuseppe LicataSergio FasulloCaterina TrapanesePietro Di PasqualeMichele Bellancasubject
Malemedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina InternaPost dischargeFluid intakeQuality of lifeAmbulatory careFurosemideAmbulatory CareInternal MedicinemedicineHumansDiureticsIntensive care medicineAgedHeart Failurebusiness.industryheart failure ambulatory follow-up furosemidecongestion post dischargeFurosemideMiddle Agedmedicine.diseasePatient DischargeTreatment OutcomeHeart failureAmbulatoryEmergency MedicineFluid TherapyFemalebusinessBioelectrical impedance analysisFollow-Up Studiesmedicine.drugdescription
Congestive heart failure (CHF) worsening is a worldwide cause of rehospitalization and mortality, specially during the early period after hospitalization. Fluid accumulation plays a key role in the pathophysiology of both acute heart decompensation and disease progression. The effective use of drugs to maintain restored clinical stabilization in recently discharged patients is a difficult task, and it relies on matching the most appropriately tailored therapy to specific clinical profiles. However, no successful treatment has been shown to reduce post-discharge readmission. We evaluated in a case-control study the effectiveness of an early and personalized congestion-guided ambulatory program on medium-term (6 months) compensation in recently discharged CHF patients. Group A (22 patients) underwent a post-discharge close follow-up consisting of: an early clinic visit within 10 days; a second visit within 10 days after the first; and the other visits at month 1, 2, 3 after discharge. Controls (Group B, 21 patients) underwent a conventional ambulatory follow-up only at month 1, 2, 3 after discharge. The ambulatory approach in both groups was based on the monitoring of signs/symptoms of congestion and body weight, body hydration estimation by using bioelectrical impedance analysis (BIA) and laboratory data. This assessment was finalized to tailor furosemide and daily fluid intake at each visit to eliminate clinical or instrumental evidence of persistent congestion relieving the signs and symptoms. At 6 months, Group A was associated with a better clinical compensation (improved hydration state, lower BNP levels and congestion score), an improved quality of life, and reduced re-hospitalizations. We conclude that in CHF the early and personalized ambulatory follow-up based on congestion-guided treatment is effective to optimize management and maintain clinical stability in the post-discharge period.
year | journal | country | edition | language |
---|---|---|---|---|
2010-07-25 | Internal and Emergency Medicine |